Skip to main content
Top
Published in: Pediatric Nephrology 9/2020

01-09-2020 | Cushing's Syndrome | Clinical Quiz

A rare case of severe hypertension with hypokalemic metabolic alkalosis in a 14-year-old girl: Answers

Authors: Pediredla Karunakar, Sriram Krishnamurthy, Aakash Chandran Chidambaram, Jayaprakash Sahoo, Sadishkumar Kamalanathan, Sambandan Kumaravel, Bheemanathi Hanuman Srinivas, Biswajit Dubashi

Published in: Pediatric Nephrology | Issue 9/2020

Login to get access

Excerpt

1.
Our patient had metabolic alkalosis, hypokalemia, high urinary chloride, and hypertension. This situation can be approached as depicted in Fig. 1. Since the urinary chloride was high, and she had severe hypertension with hypokalemic metabolic alkalosis in the presence of rounded facies, we clinically suspected Cushing syndrome (CS) as a possible etiology, and she underwent estimation of serum cortisol along with plasma adrenocorticotropic hormone (ACTH). The history was reviewed, and she denied any history of intake of steroids or medications containing steroids. The plasma renin activity (0.2 ng/mL/h) and plasma aldosterone level (3 ng/dL) were low (reference values: plasma renin activity 0.9–6.6 ng/mL/h, plasma aldosterone level 6.5–29.5 ng/dL). This led to a clinical suspicion of endogenous CS as a potential explanation for the constellation of clinical and laboratory findings encountered in this patient.
 
2.
In view of a clinical suspicion of CS, she underwent estimation of serum cortisol (at 8 am) along with plasma adrenocorticotropic hormone (ACTH). The levels of these were found to be > 75 mcg/dL (reference value 4.3–22.4 mcg/dL) and 363 pg/mL (reference value 10–60 pg/mL) respectively. This led to a diagnosis of ACTH-dependent Cushing syndrome. MRI cranium showed no evidence of pituitary or hypothalamic lesions. A contrast-enhanced computed tomography of the thorax and abdomen was performed for further evaluation of the etiology of endogenous Cushing syndrome. This showed evidence of a tumor in the tail of the pancreas, para-aortic and coeliac lymphadenopathy, evidence of metastasis to the liver, and bilateral adrenal hyperplasia (Fig. 2). Subsequently, the patient underwent distal pancreatectomy, bilateral adrenalectomy with nodal sampling, and liver nodule excision biopsy. Histopathological examination of the excised pancreatic specimen showed monomorphic tumor cells arranged in nests and sheets which showed moderate cytoplasm, fine stippled chromatin, and moderate degree of nuclear atypia. These cells were diffusely positive for immunohistochemistry with synaptophysin and chromogranin. The Ki-67 index was 40%. Hence, the final histopathology was suggestive of a well-differentiated pancreatic neuroendocrine tumor (World Health Organization Grade 3) with metastasis to celiac lymph node and liver nodule (Fig. 3). To summarize, she had a pancreatic neuroendocrine tumor producing ACTH, leading to endogenous CS. Post-operatively, she requires amlodipine (being tapered) and hydrocortisone. Stress dose of hydrocortisone was initiated. After multidisciplinary tumor board discussion, oral capecitabine and temozolamide chemotherapy were initiated.
 
3.
The mechanisms of hypertension in endogenous CS are multifactorial. The primary mechanism is the mineralocorticoid action exerted by supraphysiological levels of serum cortisol. Serum cortisol is known to bind to both glucocorticoid and mineralocorticoid receptors [1]. The plasma levels of cortisol in humans are 100–1000-fold higher than that of aldosterone which implies that mineralocorticoid receptor (MR) can be chiefly activated by cortisol. However, this is kept in check by 11β-hydroxy steroid dehydrogenase (11β-HSD) which modulates the effect of cortisol at the tissue level. There are two isoforms of 11β-HSD enzyme. The first isoform 11β-HSD1 catalyzes both dehydrogenation and reduction reactions and is responsible for the interconversion of cortisol and cortisone. In vivo, it predominantly functions as a reductase, converting inactive cortisone to active cortisol. It is abundantly expressed in the liver and adipose tissue. The second isoform 11β- HSD2 is active at very low cortisol concentrations and has mainly dehydrogenase activity which inactivates cortisol to cortisone. It is highly expressed in mineralocorticoid target tissues like renal cortex, colon, salivary, and sweat glands. This enzyme prevents cortisol from binding to MR in mineralocorticoid target tissues under physiological concentrations of cortisol. However, in cortisol excess states, the levels of cortisol would exceed the capacity of 11β-HSD to inactivate it to cortisone, thus making it available to bind to MR, mimicking excess aldosterone. This MR activation in turn results in increased renal tubular sodium reabsorption and intravascular volume expansion. Mineralocorticoid-induced hypertension is due to over activity of epithelial Na+ (ENac) [2] (Fig. 4). MR activity also leads to ROMK channel and H+K+ATPase stimulation in the distal nephron, leading to hypokalemia and metabolic alkalosis, respectively.
 
Literature
1.
go back to reference Magiakou MA, Smyrnaki P, Chrousos GP (2006) Hypertension in Cushing’s syndrome. Best Pract Res Clin Endocrinol Metab 20:467–482CrossRef Magiakou MA, Smyrnaki P, Chrousos GP (2006) Hypertension in Cushing’s syndrome. Best Pract Res Clin Endocrinol Metab 20:467–482CrossRef
2.
go back to reference Cicala MV, Mantero F (2010) Hypertension in Cushing’s syndrome: from pathogenesis to treatment. Neuroendocrinology. 92(Suppl 1):44–49CrossRef Cicala MV, Mantero F (2010) Hypertension in Cushing’s syndrome: from pathogenesis to treatment. Neuroendocrinology. 92(Suppl 1):44–49CrossRef
3.
go back to reference Kirilov G, Tomova A, Dakovska L, Kumanov P, Shinkov A, Alexandrov AS (2003) Elevated plasma endothelin as an additional cardiovascular risk factor in patients with Cushing’s syndrome. Eur J Endocrinol 149:549–553CrossRef Kirilov G, Tomova A, Dakovska L, Kumanov P, Shinkov A, Alexandrov AS (2003) Elevated plasma endothelin as an additional cardiovascular risk factor in patients with Cushing’s syndrome. Eur J Endocrinol 149:549–553CrossRef
4.
go back to reference Mangos GJ, Whitworth JA, Williamson PM, Kelly JJ (2003) Glucocorticoids and the kidney. Nephrology (Carlton) 8:267–273CrossRef Mangos GJ, Whitworth JA, Williamson PM, Kelly JJ (2003) Glucocorticoids and the kidney. Nephrology (Carlton) 8:267–273CrossRef
5.
go back to reference Baid S, Nieman LK (2004) Glucocorticoid excess and hypertension. Curr Hypertens Rep 6:493–499CrossRef Baid S, Nieman LK (2004) Glucocorticoid excess and hypertension. Curr Hypertens Rep 6:493–499CrossRef
6.
go back to reference McFarlane SI, Banerji M, Sowers JR (2001) Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 86:713–718PubMed McFarlane SI, Banerji M, Sowers JR (2001) Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 86:713–718PubMed
7.
go back to reference Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709–717 Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709–717
8.
go back to reference Weiner ID, Wingo CS (1997) Hypokalemia--consequences, causes, and correction. J Am Soc Nephrol 8:1179–1188PubMed Weiner ID, Wingo CS (1997) Hypokalemia--consequences, causes, and correction. J Am Soc Nephrol 8:1179–1188PubMed
9.
go back to reference Etxabe J, Vazquez JA (1994) Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol 40:479–484CrossRef Etxabe J, Vazquez JA (1994) Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol 40:479–484CrossRef
10.
go back to reference Clayton RN, Raskauskiene D, Reulen RC, Jones PW (2011) Mortality and morbidity in Cushing’s disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab 96:632–642CrossRef Clayton RN, Raskauskiene D, Reulen RC, Jones PW (2011) Mortality and morbidity in Cushing’s disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab 96:632–642CrossRef
11.
go back to reference Arnardóttir S, Sigurjonsdóttir HA (2011) The incidence and prevalence of Cushing’s disease may be higher than previously thought: results from a retrospective study in Iceland 1955 through 2009. Clin Endocrinol 74:792–793CrossRef Arnardóttir S, Sigurjonsdóttir HA (2011) The incidence and prevalence of Cushing’s disease may be higher than previously thought: results from a retrospective study in Iceland 1955 through 2009. Clin Endocrinol 74:792–793CrossRef
12.
go back to reference Ragnarsson O, Olsson DS, Chantzichristos D, Papakokkinou E, Dahlqvist P, Segerstedt E, Olsson T, Petersson M, Berinder K, Bensing S, Hoybye C, Eden Engstrom B, Burman P, Bonelli L,Follin C, Petranek D, Erfurth EM, Wahlberg J, Ekman B, Akerman AK, Schwarcz E, Bryngelsson IL, Johannsson G (2019) The incidence of Cushing’s disease: a nationwide Swedish study. Pituitary. 22:179–186 Ragnarsson O, Olsson DS, Chantzichristos D, Papakokkinou E, Dahlqvist P, Segerstedt E, Olsson T, Petersson M, Berinder K, Bensing S, Hoybye C, Eden Engstrom B, Burman P, Bonelli L,Follin C, Petranek D, Erfurth EM, Wahlberg J, Ekman B, Akerman AK, Schwarcz E, Bryngelsson IL, Johannsson G (2019) The incidence of Cushing’s disease: a nationwide Swedish study. Pituitary. 22:179–186
13.
go back to reference Bolland MJ, Holdaway IM, Berkeley JE, Lim S, Dransfield WJ, Conaglen JV, Croxson MS, Gamble GD, Hunt PJ, Toomath RJ (2011) Mortality and morbidity in Cushing’s syndrome in New Zealand. Clin Endocrinol 75:436–442 Bolland MJ, Holdaway IM, Berkeley JE, Lim S, Dransfield WJ, Conaglen JV, Croxson MS, Gamble GD, Hunt PJ, Toomath RJ (2011) Mortality and morbidity in Cushing’s syndrome in New Zealand. Clin Endocrinol 75:436–442
14.
go back to reference Lindholm J, Juul S, Jørgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jorgensen J, Kosteljanetz M, Kristensen L, Laurberg P, Schmidt K, Weeke J (2001) Incidence and late prognosis of Cushing’s syndrome: a population-based study. J Clin Endocrinol Metab 86:117–123 Lindholm J, Juul S, Jørgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jorgensen J, Kosteljanetz M, Kristensen L, Laurberg P, Schmidt K, Weeke J (2001) Incidence and late prognosis of Cushing’s syndrome: a population-based study. J Clin Endocrinol Metab 86:117–123
15.
go back to reference Wengander S, Trimpou P, Papakokkinou E, Ragnarsson O (2019) The incidence of endogenous Cushing’s syndrome in the modern era. Clin Endocrinol 91:263–270CrossRef Wengander S, Trimpou P, Papakokkinou E, Ragnarsson O (2019) The incidence of endogenous Cushing’s syndrome in the modern era. Clin Endocrinol 91:263–270CrossRef
16.
go back to reference Sharma ST, Nieman LK, Feelders RA (2015) Cushing’s syndrome: epidemiology and developments in disease management. Clin Epidemiol 7:281–293PubMedPubMedCentral Sharma ST, Nieman LK, Feelders RA (2015) Cushing’s syndrome: epidemiology and developments in disease management. Clin Epidemiol 7:281–293PubMedPubMedCentral
17.
go back to reference Lodish MB, Keil MF, Stratakis CA (2018) Cushing’s syndrome in pediatrics: an update. Endocrinol Metab Clin N Am 47:451–462CrossRef Lodish MB, Keil MF, Stratakis CA (2018) Cushing’s syndrome in pediatrics: an update. Endocrinol Metab Clin N Am 47:451–462CrossRef
18.
go back to reference Stratakis CA (2012) Cushing syndrome in pediatrics. Endocrinol Metab Clin N Am 41:793–803CrossRef Stratakis CA (2012) Cushing syndrome in pediatrics. Endocrinol Metab Clin N Am 41:793–803CrossRef
19.
go back to reference Ismail H, Broniszczak D, Markiewicz-Kijewska M, Ciopiński M, Teisseyre J, Kluge P, Dembowska-Baginska B, Kosciesza A, Socha P, Kalicinski P (2016) Metastases of pancreatic neuroendocrine tumor to the liver as extremely rare indication for liver transplantation in children. Case report and review of the literature. Clin Res Hepatol Gastroenterol 40:e33–e37 Ismail H, Broniszczak D, Markiewicz-Kijewska M, Ciopiński M, Teisseyre J, Kluge P, Dembowska-Baginska B, Kosciesza A, Socha P, Kalicinski P (2016) Metastases of pancreatic neuroendocrine tumor to the liver as extremely rare indication for liver transplantation in children. Case report and review of the literature. Clin Res Hepatol Gastroenterol 40:e33–e37
20.
go back to reference Rosado B, Gores GJ (2004) Liver transplantation for neuroendocrine tumors: progress and uncertainty. Liver Transpl 10:712–713CrossRef Rosado B, Gores GJ (2004) Liver transplantation for neuroendocrine tumors: progress and uncertainty. Liver Transpl 10:712–713CrossRef
21.
go back to reference Navalkele P, O’Dorisio MS, O’Dorisio TM, Zamba GKD, Lynch CF (2011) Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: nine standard SEER registries, 1975-2006. Pediatr Blood Cancer 56:50–57CrossRef Navalkele P, O’Dorisio MS, O’Dorisio TM, Zamba GKD, Lynch CF (2011) Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: nine standard SEER registries, 1975-2006. Pediatr Blood Cancer 56:50–57CrossRef
22.
go back to reference Cives M, Strosberg JR (2018) Gastroenteropancreatic neuroendocrine tumors. Cancer J Clin 68:471–487CrossRef Cives M, Strosberg JR (2018) Gastroenteropancreatic neuroendocrine tumors. Cancer J Clin 68:471–487CrossRef
23.
go back to reference Franchi G, Manzoni MF (2014) Cytological Ki-67 in pancreatic endocrine tumors: a new “must”? Gland Surg 3:219–221PubMedPubMedCentral Franchi G, Manzoni MF (2014) Cytological Ki-67 in pancreatic endocrine tumors: a new “must”? Gland Surg 3:219–221PubMedPubMedCentral
24.
go back to reference Zimmer T, Ziegler K, Liehr RM, Stölzel U, Riecken EO, Wiedenmann B (1994) Endosonography of neuroendocrine tumors of the stomach, duodenum, and pancreas. Ann N Y Acad Sci 733:425–436CrossRef Zimmer T, Ziegler K, Liehr RM, Stölzel U, Riecken EO, Wiedenmann B (1994) Endosonography of neuroendocrine tumors of the stomach, duodenum, and pancreas. Ann N Y Acad Sci 733:425–436CrossRef
25.
go back to reference Binstock AJ, Johnson CD, Stephens DH, Lloyd RV, Fletcher JG (2001) Carcinoid tumors of the stomach: a clinical and radiographic study. Am J Roentgenol 176:947–951CrossRef Binstock AJ, Johnson CD, Stephens DH, Lloyd RV, Fletcher JG (2001) Carcinoid tumors of the stomach: a clinical and radiographic study. Am J Roentgenol 176:947–951CrossRef
26.
go back to reference Dolcetta-Capuzzo A, Villa V, Albarello L, Franchi GM, Gemma M, Scavini M, Di Palo S, Orsenigo E, Bosi E, Doglioni C, Manzoni MF (2013) Gastroenteric neuroendocrine neoplasms classification: comparison of prognostic models. Cancer. 119:36–44 Dolcetta-Capuzzo A, Villa V, Albarello L, Franchi GM, Gemma M, Scavini M, Di Palo S, Orsenigo E, Bosi E, Doglioni C, Manzoni MF (2013) Gastroenteric neuroendocrine neoplasms classification: comparison of prognostic models. Cancer. 119:36–44
27.
go back to reference Gu P, Wu J, Newman E, Muggia F (2012) Treatment of liver metastases in patients with neuroendocrine tumors of gastroesophageal and pancreatic origin. Int J Hepatol 2012:131659CrossRef Gu P, Wu J, Newman E, Muggia F (2012) Treatment of liver metastases in patients with neuroendocrine tumors of gastroesophageal and pancreatic origin. Int J Hepatol 2012:131659CrossRef
Metadata
Title
A rare case of severe hypertension with hypokalemic metabolic alkalosis in a 14-year-old girl: Answers
Authors
Pediredla Karunakar
Sriram Krishnamurthy
Aakash Chandran Chidambaram
Jayaprakash Sahoo
Sadishkumar Kamalanathan
Sambandan Kumaravel
Bheemanathi Hanuman Srinivas
Biswajit Dubashi
Publication date
01-09-2020
Publisher
Springer Berlin Heidelberg
Published in
Pediatric Nephrology / Issue 9/2020
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-020-04509-3

Other articles of this Issue 9/2020

Pediatric Nephrology 9/2020 Go to the issue